Corrigendum to Canadian Cardiovascular Society/Canadian Heart Failure Society 2025 Guideline Update for Pharmacologic Management of Heart Failure With Nonreduced Ejection Fraction (LVEF > 40%)

Structured PICO

P

Population

People with heart failure with nonreduced ejection fraction (HFnrEF, LVEF > 40%)

I

Intervention

GLP-1 receptor agonists

This corrigendum corrects a figure reference and adds a dosing step for GLP-1 receptor agonists in the 2025 CCS/CHFS HFnrEF guidelines.

Updates dosing for GLP-1 RAs in HFnrEF; extends 2025 CCS/CHFS guidelines with practical titration guidance.

No abstract yet. The journal hasn't published one we can show.

No takes yet. Share an insight, caveat, or question.

Virani et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Share